4.8 Review

Severe cutaneous adverse reactions to drugs

Journal

LANCET
Volume 390, Issue 10106, Pages 1996-2011

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30378-6

Keywords

-

Funding

  1. Janssen Cilag
  2. Novartis
  3. Roche
  4. Sanofi-Aventis
  5. Abbvie
  6. GlaxoSmithKline
  7. Bailleul
  8. Astellas
  9. Galderma
  10. Bayer
  11. Pierre Fabre
  12. Expanscience
  13. Cephalon
  14. Boehringer Ingelheim

Ask authors/readers for more resources

During the past decade, major advances have been made in the accurate diagnosis of severe cutaneous adverse reactions (SCARs) to drugs, management of their manifestations, and identification of their pathogenetic mechanisms and at-risk populations. Early recognition and diagnosis of SCARs are key in the identification of culprit drugs. SCARS are potentially life threatening, and associated with various clinical patterns and morbidity during the acute stage of Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reactions with eosinophilia and systemic symptoms, and acute generalised exanthematous pustulosis. Early drug withdrawal is mandatory in all SCARs. Physicians' knowledge is essential to the improvement of diagnosis and management, and in the limitation and prevention of long-term sequelae. This Seminar provides the tools to help physicians in their clinical approach and investigations of SCARs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available